Montelukast for Postinfectious Cough

• Status: Unknown status
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Cough is a common symptom of respiratory medicine clinic patients, which has complex etiology and wide-ranging. Cough is usually divided into three categories by time: acute cough, subacute cough and chronic cough. Subacute has a 3~8 weeks course of disease. Its main etiology is postinfectious cough, which is mostly secondary to viral infection.Considering its overexpression in postinfectious patient, Cysteinyl leukotriene (CysLTs) plays a role in gathering eosinophils to respiratory. The level of FENO has a significant correlation with inflammatory airway eosinophils. While CysLTs overexpressed in vivo, the level of FENO may increase. Montelukast, as CysLTs-receptor-1 antagonists， plays a role of controlling airway inflammation and decrease airway high activity by suppressing the biological activity of CysLTs. It is effective in theory to therapy sub-acute cough by Montelukast, to short the course and to relieve cough symptoms as soon as possible. The aim is to research whether FENO can be used as a biomarker to optimized treatment regimen of sub-acute cough.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Chao Yang Hospital
• Treatments: Montelukast

Criteria

Inclusion Criteria:

• Cough is the main or only clinical symptom and was persistent for 3-8 weeks

• Chest X-ray reveals no noticeable pathological changes

• 18 year old, regardless of gender and ethical background

• Not taking angiotensin-converting enzyme inhibitor

• Patients must join the programme voluntarily and are able to attend examination and follow-up sessions

Exclusion Criteria:

• Patients diagnosed with allergic rhinitis, chronic nasosinusitis or bacterial respiratory tract infections

• Patients diagnosed with severe reportorial disease of other severe systemic disease

• Patients who are allergic to any drugs to be tested

• Patients who are non-cooperative during examination sessions or other steps of the trial

• Patients who are not able to or refuse to sign consent